Pfizer raises US prices for more than 100 drugs
Add BT as a preferred source
London
PFIZER Inc, which plans a US$160 billion merger with Ireland-based Allergan Plc to slash its US tax bill, on Jan 1 raised US prices for more than 100 of its drugs, some by as much as 20 per cent, according to statistics compiled by global information services company Wolters Kluwer.
Pfizer confirmed a 9.4 per cent increase for heavily advertised pain drug Lyrica, which generated US$2.3 billion in 2014 US sales; a 12.9 per cent increase for erectile dysfunction drug Viagra, which had 2014 US sales of US$1.1 billion; and a 5 per cent increase for Ibrance, a novel breast cancer drug launched last year at a list price of US$9,850 per month, or US$118,200 per year.
TRENDING NOW
Singtel Q1 gain drops 71% to S$818 million in absence of Airtel stake sale; weaker Singapore business
Sembcorp raises interim dividend despite 72% H1 profit slide to S$150 million on Alinta deal costs
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
CDL H1 profit jumps three times to S$301 million on strong condo sales, doubles interim dividend
